My Sanford Chart allows you secure online access to your personal health information and your child's health information. It's available anywhere you have internet access. There is no cost to you and registering is quick and simple.

Sign Up for My Sanford Chart
Study ID: NSABP B-43
Title:

Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy

Description:

This study is being done to compare the effects, good and/or bad, of adding the drug trastuzumab (also called Herceptin®) to breast radiation therapy. Participants in this study have been diagnosed with a very early stage of breast cancer called ductal carcinoma in situ (DCIS). DCIS is also known as intraductal or non-invasive breast cancer. DCIS means that the cancer cells are only in the milk ducts in the breast and have not spread to other breast tissue or to other parts of the body. Radiation therapy is the standard treatment for patients with DCIS.

Location:
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Principal Investigator:
Miroslaw Mazurczak MD;Miroslaw Mazurczak MD,Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Disease:
DCIS, Cancer Control
Stage:
Phase III

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list